Core B - Experimental Glioma Animal Models Core This core facility will assist each Project Leader in this Program Project Grant to test, in relevant animal models of brain tumors, preclinical safety and efficacy of various therapies designed to achieve an improved anti-glioma effect The animal models we will employ are likely to identify both toxicity and efficacy of therapeutic modalities that might be advanced to treat patients with malignant brain tumors. This core will centralize animal experimentation associated with this Program, standardizing expert surgical and animal handling techniques and minimizing chances for trivial interferences that could hamper comparative analyses. Tumor volume, tumor mass and survival statistics will be collected where appropriate. Normal and tumor tissues will be collected and submitted to each investigator or will be processed in this core for gene expression or histopathologic analyses. Project 1 will require glioma xenografts in immunocompromised mice to determine the safety and efficacy of wild-type HSV-1 engineered to target human malignant glioma cells expressing unique receptor molecules. Hybridomas expressing anti-CDI 33 will be produced in the Core to acquire single chain antibody DNA. Project 2 will evaluate the capacity of a AYI34.5 HSV engineered to express activated MEK to facilitate HSV late gene expression in human glioma xenografts in the brains of nude mice. Project 3 will examine the susceptibility of human glioma progenitor cells in human glioma xenografts to genetically engineered HSV to define virus-host cell interactions and to characterize and improve HSV-mediated oncolysis of gliomas. Project 4 will characterize virus-host interactions in brain tumor tissues from a Phase I clinical trials with M032 (human IL-12 expressing). The Core will assist with development of animal brain tumor models to test findings from these correlative studies with human glioma specimens. Bioluminescence imaging to monitor glioma growth and response to therapy will be coordinated by the Core. The Core will assist with pre-IND safety studies in HSV-sensitive New-World owl monkeys (Aotus spp.) or marmosets (Callithrix spp) conducted to define any unanticipated toxicities to primate brain The Core will coordinate with the 8.5T/9.4T Small Animal NMR Facility for all NMR imaging studies of tumor- bearing mice involved in these preclinical evaluations and will coordinate with the 4.7T nonhuman primate NMR for imaging and spectroscopic studies. Finally, the Core will continue to evaluate serially passaged human glioma xenografts as well as specific transgenic models for preclinical toxicity and efficacy analyses for each ofthe unique genetically engineered HSV developed and/or characterized by Projects 1, 2 and 3.
The EGAM Core is an essential component to the process of translating novel therapies from the laboratory to clinical application. Animal testing, performed in a highly standardized fashion by trained, skilled and experienced professionals, is a prerequisite for FDA approval to initiate-IRB approved clinical trials in humans. Moreover, our brain tumor models replicate, in most ways, the biology and physiology of high grade gliomas in patients and as such can be predictive of the likelihood of success or failure of novel therapies.
|Friedman, G K; Nan, L; Haas, M C et al. (2015) ??34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia. Gene Ther 22:348-55|
|Jackson, J D; McMorris, A M; Roth, J C et al. (2014) Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. Gene Ther 21:984-90|
|Cody, James J; Markert, James M; Hurst, Douglas R (2014) Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells. PLoS One 9:e92919|
|Roth, Justin C; Cassady, Kevin A; Cody, James J et al. (2014) Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev 25:16-27|
|Widau, Ryan C; Parekh, Akash D; Ranck, Mark C et al. (2014) RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation. Proc Natl Acad Sci U S A 111:E484-91|
|Smith, Tyrel T; Roth, Justin C; Friedman, Gregory K et al. (2014) Oncolytic viral therapy: targeting cancer stem cells. Oncolytic Virother 2014:21-33|
|Markert, James M; Razdan, Shantanu N; Kuo, Hui-Chien et al. (2014) A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther 22:1048-55|
|Pressey, Joseph G; Haas, Marilyn C; Pressey, Christine S et al. (2013) CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV. Pediatr Blood Cancer 60:45-52|
|Liauw, Stanley L; Connell, Philip P; Weichselbaum, Ralph R (2013) New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med 5:173sr2|
|Gillory, Lauren A; Megison, Michael L; Stewart, Jerry E et al. (2013) Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma. PLoS One 8:e77753|
Showing the most recent 10 out of 150 publications